Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry-Reference-Cited by-同舟云学术

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

Published:2017-04-09 Issue:1 Volume:21 Page:96-105
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Carmona-Bayonas A., ,Jiménez-Fonseca P.,Custodio A.,Sánchez Cánovas M.,Hernández R.,Pericay C.,Echavarria I.,Lacalle A.,Visa L.,Rodríguez Palomo A.,Mangas M.,Cano J. M.,Buxo E.,Álvarez-Manceñido F.,García T.,Lorenzo J. E.,Ferrer-Cardona M.,Viudez A.,Azkarate A.,Ramchandani A.,Arias D.,Longo F.,López C.,Sánchez Bayona R.,Limón M. L.,Díaz-Serrano A.,Fernández Montes A.,Sala P.,Cerdá P.,Rivera F.,Gallego J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s10120-017-0718-5/fulltext.html

Reference30 articles.

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

2. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbb-2 in human gastric cancer. Cancer. 1995;75:1418–25.

3. Jiménez-Fonseca P, Carmona-Bayonas A, Lorenzo MLS, Plazas JG, Custodio A, Hernández R, et al. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer. 2016. doi: 10.1007/s10120-016-0639-8 .

4. Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS, Ramchandani A, Martínez EA, Custodio A, et al. On the effect of triplet or doublet chemotherapy in advanced gastric cancer: results from a National Cancer Registry. J Natl Compr Cancer Netw. 2016;14:1379–88. http://www.jnccn.org/content/14/11/1379.abstract . Accessed 7 Apr 2017.

5. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. The Cochrane database of systematic reviews (internet). 2016;CD004064. http://www.ncbi.nlm.nih.gov/pubmed/20238327 . Accessed 7 Apr 2017.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry;Journal of Cancer Research and Clinical Oncology;2022-08-30

2. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry;ESMO Open;2022-06

3. Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry;Biomedicines;2022-01-11

4. A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma;Therapeutic Advances in Medical Oncology;2022-01

5. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma;Gastric Cancer;2021-03-23